Management of facial flushing in rosacea

Mirvaso® is the first topical a2-receptor agonist licensed for treating persistent facial flushing in rosacea, which can have a huge psychological impact on sufferers

Source: Pharmacy Europe - August 8, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news